Table 1. Demographic characteristics, treatment and outcome data for CUP patients.
| Alla (%) n=106 641 | Adeno CA n=38 511 (36.1%) | Squamous n=9058 (8.5%) | NOS n=32 357 (30.3%) | Neuroendocrine n=3390 (3.2%) | |
|---|---|---|---|---|---|
|
Gender (males) | |||||
| |
50 994 (47.8%) |
17 033 (44.2) |
6102 (67.4) |
15 690 (48.5) |
1655 (48.8) |
|
Median age (range) | |||||
| |
72 (0–113) |
70 (0–106) |
65 (2–103) |
74 (0–113) |
66 (13–85) |
|
Gradeb | |||||
| 1 | 954 (4.9%) | 497 (6.1%) | 180 (7.8%) | 17 (0.3) | 91 (20.1%) |
| 2 | 3074 (15.8%) | 1946 (24.1%) | 670 (29.2%) | 52 (0.8) | 65 (14.4%) |
| 3 | 10 911 (56.1%) | 5244 (64.8%) | 1347 (58.7%) | 3112 (47.3%) | 196 (43.4%) |
| 4 |
4517 (23.2%) |
402 (5.0%) |
99 (4.3%) |
3397 (51.6%) |
100 (22.1%) |
|
Race | |||||
| White | 88 814 (83.7%) | 31 638 (82.5%) | 7683 (85.7%) | 27 263 (84.6%) | 2843 (84.1%) |
| Black | 11 098 (10.5%) | 4189 (10.9%) | 885 (9.9%) | 3174 (9.9%) | 393 (11.6%) |
| Other |
6227 (5.9%) |
2524 (6.6%) |
395 (4.4%) |
1798 (5.6%) |
143 (4.2%) |
|
Radiotherapy | |||||
| None | 83 555 (79.7%) | 30 770 (81.0%) | 4044 (45.8%) | 26 109 (81.8%) | 2871 (86.2%) |
| Radiotherapy | 20 182 (19.2%) | 6917 (18.2%) | 4682 (53.0%) | 5421 (17.0%) | 438 (13.2%) |
| Refused |
1168 (1.1%) |
295 (0.8%) |
101 (1.1%) |
381 (1.2%) |
20 (0.6%) |
|
Marital | |||||
| Married | 49 780 (49.0%) | 19 307 (52.4%) | 4653 (54.6%) | 14 490 (46.9%) | 1857 (57.3%) |
| Single | 13 186 (13.0%) | 4519 (12.3%) | 1278 (15.0%) | 3823 (12.4%) | 437 (13.5%) |
| Previously married |
38 645 (38.0%) |
13 026 (35.4%) |
2599 (30.5%) |
12 567 (40.7%) |
947 (29.2%) |
|
Median survival months (range) | |||||
| 2 (0–430)c | 2 (0–394) | 15 (0–400) | 2 (0–426) | 11 (0–334) | |
Abbreviations: CA=carcinoma; CUP=carcinoma of unknown primary; NOS=not otherwise specified.
a
Other histologies included unspecified (15%), sarcoma (<1%) and others (1%).
b
Data on grade were available for 19 456 patients.
c
This is the only survival analysis that included all CUP patients. All other survival analyses were limited to patients with carcinoma.